Luther King Capital Management (LKCM)’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$35.4M Buy
582,998
+51,712
+10% +$3.01M 0.15% 100
2025
Q4
$28.7M Buy
531,286
+13,300
+3% +$640K 0.12% 119
2025
Q3
$23.4M Sell
517,986
-18,602
-3% -$869K 0.1% 125
2025
Q2
$24.8M Buy
536,588
+287,201
+115% +$14.1M 0.11% 120
2025
Q1
$15.2M Buy
249,387
+227,332
+1,031% +$13.3M 0.07% 143
2024
Q4
$1.25M Sell
22,055
-1,302
-6% -$72.7K 0.01% 379
2024
Q3
$1.21M Sell
23,357
-332
-1% -$15.6K 0.01% 384
2024
Q2
$984K Sell
23,689
-10,298
-30% -$461K ﹤0.01% 404
2024
Q1
$1.84M Buy
33,987
+10,171
+43% +$518K 0.01% 333
2023
Q4
$1.22M Sell
23,816
-6,522
-21% -$342K 0.01% 371
2023
Q3
$1.76M Buy
30,338
+2,080
+7% +$127K 0.01% 322
2023
Q2
$1.81M Sell
28,258
-944
-3% -$63.3K 0.01% 334
2023
Q1
$2.02M Sell
29,202
-4,423
-13% -$312K 0.01% 301
2022
Q4
$2.42M Buy
33,625
+1,382
+4% +$104K 0.01% 282
2022
Q3
$2.29M Buy
32,243
+248
+0.8% +$18K 0.01% 280
2022
Q2
$2.46M Buy
31,995
+8,935
+39% +$681K 0.01% 269
2022
Q1
$1.68M Buy
23,060
+1,109
+5% +$74.5K 0.01% 327
2021
Q4
$1.37M Sell
21,951
-1,523
-6% -$89.3K 0.01% 367
2021
Q3
$1.39M Sell
23,474
-4,600
-16% -$303K 0.01% 363
2021
Q2
$1.88M Sell
28,074
-97,648
-78% -$6.37M 0.01% 328
2021
Q1
$7.94M Sell
125,722
-181
-0.1% -$11.3K 0.04% 157
2020
Q4
$7.81M Buy
125,903
+1,648
+1% +$101K 0.04% 157
2020
Q3
$7.49M Sell
124,255
-17
-0% -$1.02K 0.05% 145
2020
Q2
$7.31M Hold
124,272
0.05% 149
2020
Q1
$6.93M Sell
124,272
-125
-0.1% -$7.64K 0.06% 138
2019
Q4
$7.99M Sell
124,397
-1,757
-1% -$101K 0.05% 156
2019
Q3
$6.4M Sell
126,154
-8,309
-6% -$391K 0.05% 160
2019
Q2
$6.1M Sell
134,463
-23,854
-15% -$1.11M 0.04% 166
2019
Q1
$7.55M Buy
158,317
+12,544
+9% +$625K 0.06% 158
2018
Q4
$7.58M Sell
145,773
-4,682
-3% -$252K 0.07% 147
2018
Q3
$9.34M Sell
150,455
-7,103
-5% -$422K 0.07% 150
2018
Q2
$8.72M Sell
157,558
-8,487
-5% -$458K 0.07% 149
2018
Q1
$10.5M Buy
166,045
+474
+0.3% +$30.5K 0.09% 138
2017
Q4
$10.1M Buy
165,571
+111,275
+205% +$6.96M 0.08% 147
2017
Q3
$3.46M Sell
54,296
-8,662
-14% -$506K 0.03% 224
2017
Q2
$3.51M Sell
62,958
-3,301
-5% -$180K 0.03% 228
2017
Q1
$3.6M Sell
66,259
-1,081
-2% -$59.3K 0.03% 236
2016
Q4
$3.94M Buy
67,340
+1,161
+2% +$63.5K 0.04% 242
2016
Q3
$3.57M Sell
66,179
-1,847
-3% -$119K 0.03% 252
2016
Q2
$5M Buy
68,026
+2,007
+3% +$142K 0.05% 234
2016
Q1
$4.22M Sell
66,019
-19,110
-22% -$1.21M 0.04% 246
2015
Q4
$5.86M Sell
85,129
-1,138
-1% -$75.2K 0.05% 234
2015
Q3
$5.11M Buy
86,267
+53,133
+160% +$3.37M 0.05% 244
2015
Q2
$2.21M Buy
33,134
+4,716
+17% +$311K 0.02% 308
2015
Q1
$1.83M Buy
28,418
+2,606
+10% +$163K 0.02% 312
2014
Q4
$1.52M Buy
25,812
+1,548
+6% +$87.3K 0.01% 334
2014
Q3
$1.24M Buy
24,264
+728
+3% +$36.4K 0.01% 356
2014
Q2
$1.14M Buy
23,536
+6,664
+39% +$328K 0.01% 364
2014
Q1
$877K Buy
16,872
+6,291
+59% +$335K 0.01% 393
2013
Q4
$562K Sell
10,581
-8,547
-45% -$435K ﹤0.01% 430
2013
Q3
$885K Buy
19,128
+72
+0.4% +$3.16K 0.01% 449
2013
Q2
$852K Buy
+19,056
New +$827K 0.01% 447

Other funds holding BMY

Luther King Capital Management (LKCM)'s BMY Position: Q1 2026 in Review

Luther King Capital Management (LKCM) increased its Bristol-Myers Squibb (BMY) stake by 9.7% in Q1 2026, buying an estimated $3.01M and bringing the position to 582,998 shares worth $35.4M. The position accounts for 0.15% of the portfolio, ranked #100.

Luther King Capital Management (LKCM) first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. 2,519 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Luther King Capital Management (LKCM) held 582,998 shares of Bristol-Myers Squibb worth $35.4M as of Q1 2026.
  • Luther King Capital Management (LKCM) bought 51,712 Bristol-Myers Squibb shares in Q1 2026, an estimated $3.01M.
  • Bristol-Myers Squibb made up 0.15% of Luther King Capital Management (LKCM)'s portfolio in Q1 2026, its #100 holding.
  • Luther King Capital Management (LKCM) first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • 2,519 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Luther King Capital Management (LKCM)'s 13F filing for Q1 2026, filed 11 May 2026.